nejm semaglutide heart failure 📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for or all-cause mortality vs sitagliptin, but tirzepatide offered no Semaglutide in Patients with Heart

2023 Oct;17(10):102849.

Pramlintide, an analog of amylin, was approved by the FDA for diabetes treatment in 2005 and is given by injection three times daily with meals

2026 Hillary Lin, MD All rights reserved This content is educational and isn't medical advice

According to the National Institute of Diabetes and Kidney Diseases website: Perhaps the rapid weight loss achieved by Ozempic has further contributed to gallbladder issues, which plaintiffs claim they were not properly warned about

These medications appear to shift the fat, as well, increasing the type that is right under your skin and thus giving you a more balanced look